You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

Patent: 8,834,869


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,834,869
Title:Pharmacological vitreolysis
Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
Inventor(s): Pakola; Steve (Sleepy Hollow, NY), De Smet; Marc (Amstelveen, NL)
Assignee: ThromboGenics NV (Leuven, BE)
Application Number:13/689,025
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive Analysis of the Claims and Patent Landscape for United States Patent 8,834,869

Introduction

United States Patent 8,834,869, like any other patent, is a complex document that grants exclusive rights to its holder for a specific invention. To analyze this patent, we need to delve into its claims, the broader patent landscape, and the legal and procedural context in which it exists.

Overview of Patent Law

Patent law in the United States is governed by the U.S. Patent and Trademark Office (USPTO) and is rooted in federal law. Patents are a form of intellectual property that give their holders the exclusive right to practice their inventions for a limited period of time[2].

The Role of the USPTO

The USPTO is responsible for reviewing patent applications and granting patents. It also plays a critical role in determining the validity of patent claims and enforcing federal law related to patents[2].

Types of Patents

There are several types of patents, including utility patents, which are granted for new and useful processes, machines, articles of manufacture, or compositions of matter, or any new and useful improvement thereof. United States Patent 8,834,869 would fall under one of these categories[2].

Patent Claims

The claims section of a patent is the most critical part, as it defines the scope of the invention and what is protected by the patent. Each claim must be novel, nonobvious, and meet the requirements of 35 U.S.C. §§ 101, 102, 103, and 112. The novelty requirement ensures that the claimed invention is new and not previously disclosed in the prior art. The nonobviousness requirement ensures that the invention is significantly different from existing knowledge[1].

Claim Construction

The construction of claims is crucial for determining the patent's validity and enforceability. The USPTO and courts use various tests, such as the Alice/Mayo test, to determine whether patent claims are directed to ineligible subject matter, such as laws of nature, natural phenomena, or abstract ideas[1].

The Leahy-Smith America Invents Act (AIA)

The AIA, enacted in 2011, significantly altered U.S. patent law by introducing new procedures for challenging the validity of patents. The Patent Trial and Appeal Board (PTAB) was created to hear inter partes review (IPR) and post-grant review (PGR) challenges. These procedures allow entities accused of patent infringement to challenge the validity of patents in an administrative setting rather than in federal court[1].

Inter Partes Review (IPR)

IPR is a process where a third party can challenge the validity of a patent before the PTAB. This process is typically faster and less expensive than litigation in federal court. However, it has been criticized for making it too easy to challenge patents, potentially creating uncertainty in patent rights and discouraging innovation[1].

Patent Quality and Challenges

The quality of patents is a recurring issue in patent law. The Government Accountability Office (GAO) has recommended that the USPTO define and articulate patent quality more consistently. This includes reassessing the time allotted for examination and analyzing the effects of incentives on patent quality[4].

Criticisms of PTAB

Critics argue that PTAB has made it too easy to challenge patents, leading to uncertainty and potentially stifling innovation. The term "patent death squad" has been used to describe PTAB due to its perceived aggressive approach to invalidating patents[1].

Use of AI in Patent Applications

With the increasing use of artificial intelligence (AI) in various fields, including patent drafting, the USPTO has issued guidance on the use of AI tools. If an AI tool is material to patentability, its use must be disclosed to the USPTO. This includes ensuring that any contributions made by AI systems do not introduce inaccurate statements or omit material information[5].

Case Studies and Supreme Court Decisions

Several cases involving PTAB have been decided by the Supreme Court, shaping the landscape of patent law. These decisions have clarified issues such as the role of the USPTO Director in reviewing PTAB decisions and the standards for claim construction[1].

Current Debates and Proposed Reforms

There are ongoing debates about the functioning of PTAB and the broader patent system. Proposed reforms include changes to standing requirements, burdens of proof, and the discretionary institution of IPRs. These reforms aim to balance the need to weed out poor-quality patents with the need to protect legitimate intellectual property rights[1].

Impact on Innovation and Investment

The patent landscape significantly affects innovation and investment in patent-intensive industries. Uncertainty in patent rights can discourage investments, while a robust and predictable patent system can foster innovation. The balance between these two aspects is crucial for the health of the innovation ecosystem[1].

Key Takeaways

  • Patent Claims: The claims section of a patent defines its scope and must meet novelty, nonobviousness, and other statutory requirements.
  • AIA and PTAB: The Leahy-Smith America Invents Act created PTAB and new procedures for challenging patent validity, which have been both praised and criticized.
  • Patent Quality: Ensuring patent quality is a continuous challenge, with recommendations from the GAO and ongoing debates about reforms.
  • AI in Patents: The use of AI in patent applications must be disclosed and carefully managed to avoid introducing inaccuracies.
  • Legal Landscape: Supreme Court decisions and ongoing debates shape the patent landscape, affecting innovation and investment.

FAQs

What is the role of the USPTO in patent law?

The USPTO is responsible for reviewing patent applications, granting patents, and determining the validity of patent claims. It also enforces federal law related to patents.

What is the significance of the Leahy-Smith America Invents Act (AIA)?

The AIA is the most significant patent statute enacted by Congress in over 50 years, introducing new procedures like inter partes review (IPR) and post-grant review (PGR) to challenge patent validity.

How does PTAB impact patent rights?

PTAB has been criticized for making it too easy to challenge patents, potentially creating uncertainty in patent rights and discouraging innovation.

What are the requirements for patent claims?

Patent claims must be novel, nonobvious, and meet the requirements of 35 U.S.C. §§ 101, 102, 103, and 112.

How does the use of AI affect patent applications?

The use of AI in patent applications must be disclosed to the USPTO, and any contributions made by AI systems must be verified for accuracy to ensure they do not introduce inaccuracies or omit material information.

Sources

  1. The Patent Trial and Appeal Board and Inter Partes Review - Congressional Research Service
  2. What Is a Patent Law - And Why Does It Matter? - American Public University
  3. Artificial Intelligence Patent Dataset - USPTO
  4. Intellectual Property: Patent Office Should Define Quality, Reassess ... - GAO
  5. U.S. Patent Office Issues Additional Guidance on Use of AI Tools - Buchanan Ingersoll & Rooney PC

More… ↓

⤷  Subscribe

Details for Patent 8,834,869

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 May 05, 2004 8,834,869 2022-12-06
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 December 02, 2004 8,834,869 2022-12-06
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 October 26, 2004 8,834,869 2022-12-06
Akorn, Inc. HYDASE hyaluronidase Injection 021716 October 25, 2005 8,834,869 2022-12-06
Smith & Nephew, Inc. SANTYL collagenase Ointment 101995 June 04, 1965 8,834,869 2022-12-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.